1. Home
  2. TRNO vs GRFS Comparison

TRNO vs GRFS Comparison

Compare TRNO & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terreno Realty Corporation

TRNO

Terreno Realty Corporation

N/A

Current Price

$62.65

Market Cap

6.8B

Sector

Finance

ML Signal

N/A

Logo Grifols S.A.

GRFS

Grifols S.A.

N/A

Current Price

$8.03

Market Cap

5.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TRNO
GRFS
Founded
2009
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.8B
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
TRNO
GRFS
Price
$62.65
$8.03
Analyst Decision
Buy
Hold
Analyst Count
12
2
Target Price
$67.83
$10.15
AVG Volume (30 Days)
585.0K
646.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.29%
1.74%
EPS Growth
103.65
N/A
EPS
3.91
N/A
Revenue
$476,383,000.00
N/A
Revenue This Year
$7.62
$5.33
Revenue Next Year
$8.75
$6.50
P/E Ratio
$16.15
$18.67
Revenue Growth
24.51
N/A
52 Week Low
$53.00
$6.19
52 Week High
$67.70
$11.14

Technical Indicators

Market Signals
Indicator
TRNO
GRFS
Relative Strength Index (RSI) 40.85 30.37
Support Level $59.00 $7.64
Resistance Level $62.75 $9.11
Average True Range (ATR) 1.20 0.30
MACD -0.53 -0.11
Stochastic Oscillator 32.23 4.38

Price Performance

Historical Comparison
TRNO
GRFS

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: